MX2010002002A - Peptido foxm1 y agente medicinal que lo contiene. - Google Patents

Peptido foxm1 y agente medicinal que lo contiene.

Info

Publication number
MX2010002002A
MX2010002002A MX2010002002A MX2010002002A MX2010002002A MX 2010002002 A MX2010002002 A MX 2010002002A MX 2010002002 A MX2010002002 A MX 2010002002A MX 2010002002 A MX2010002002 A MX 2010002002A MX 2010002002 A MX2010002002 A MX 2010002002A
Authority
MX
Mexico
Prior art keywords
peptide
amino acid
foxm1
cell
same
Prior art date
Application number
MX2010002002A
Other languages
English (en)
Inventor
Yusuke Nakamura
Takuya Tsunoda
Yasuharu Nishimura
Michiko Harao
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2010002002A publication Critical patent/MX2010002002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un objeto es proporcionado en un medio que permita una inmunoterapia de cáncer para aproximadamente el 30% de los diversos tipos de pacientes con cáncer en Japón, que expresan el cuadro de Forkhead M1 (FOXM1) en altos niveles, identificando un péptido derivado de FOXM1 que enlaza a HLAA2 para activar la célula T exterminadora humana que puede exterminar una célula de cáncer. Se describe en forma específica un péptido seleccionado de los siguientes incisos (A) y (B): (A) un péptido que comprende una secuencia de aminoácido ilustrada en cualesquiera de las SEQ ID Nos: 1 a 3; y (B) un péptido que tiene la substitución, eliminación, inserción y/o adición de uno, dos o diversos residuos de aminoácidos en un péptido que comprende una secuencia de aminoácido ilustrada en cualesquiera de las SEQ ID Nos: 1 a 3, y que tiene una actividad de inducción de célula T citotóxica (exterminadora).
MX2010002002A 2007-08-20 2008-08-12 Peptido foxm1 y agente medicinal que lo contiene. MX2010002002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007214001 2007-08-20
PCT/JP2008/064437 WO2009025196A1 (ja) 2007-08-20 2008-08-12 Foxm1ペプチドおよびこれを含む薬剤

Publications (1)

Publication Number Publication Date
MX2010002002A true MX2010002002A (es) 2010-03-11

Family

ID=40378102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002002A MX2010002002A (es) 2007-08-20 2008-08-12 Peptido foxm1 y agente medicinal que lo contiene.

Country Status (15)

Country Link
US (3) US8569244B2 (es)
EP (3) EP2189471B1 (es)
JP (2) JP5555952B2 (es)
KR (1) KR101543624B1 (es)
CN (3) CN101835792B (es)
AU (1) AU2008290049B2 (es)
BR (1) BRPI0815577A2 (es)
CA (1) CA2696597C (es)
HK (1) HK1244819A1 (es)
IL (1) IL203899A (es)
MX (1) MX2010002002A (es)
RU (1) RU2487886C2 (es)
SG (1) SG183717A1 (es)
TW (1) TWI558411B (es)
WO (1) WO2009025196A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305811A1 (en) * 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
WO2009025196A1 (ja) 2007-08-20 2009-02-26 Oncotherapy Science, Inc. Foxm1ペプチドおよびこれを含む薬剤
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
MX2016001963A (es) 2013-08-19 2016-05-26 Hoffmann La Roche Metodo de seleccion.
US20150308094A1 (en) * 2014-02-21 2015-10-29 Thermaco, Inc. System and control for grease removal
US10828353B2 (en) * 2015-01-31 2020-11-10 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
SG11201802881YA (en) * 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
JP7116278B2 (ja) 2016-10-07 2022-08-10 エンテローム エスエー 癌治療のための免疫原性化合物
WO2019025433A1 (en) * 2017-08-02 2019-02-07 Idp Discovery Pharma, S.L. PEPTIDES WITH ANTICANCER ACTIVITY
CN108440671B (zh) * 2018-03-05 2020-03-06 长沙新生康源生物医药有限公司 一种来源于foxm1蛋白的抗肿瘤多肽
CN108273062A (zh) * 2018-03-29 2018-07-13 浙江大学 Foxm1抑制剂在肝内胆管细胞癌治疗中的作用
BR112020020780A2 (pt) * 2018-04-11 2021-03-02 Enterome S.A. peptídeos antigênicos para prevenção e tratamento do câncer
WO2020091052A1 (ja) 2018-11-02 2020-05-07 国立大学法人大阪大学 関節炎治療剤
CN112500457B (zh) * 2020-11-02 2022-06-17 长沙新生康源生物医药有限公司 一种双重靶向foxm1/cdk1的抗肿瘤多肽

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
JPS60217905A (ja) 1984-04-13 1985-10-31 のむら産業株式会社 自動包装機
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE69635895D1 (de) 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
EP0846761A1 (en) * 1996-12-09 1998-06-10 Introgene B.V. A novel transcription factor expressed in cycling cells, nucleic acid molecules encoding said transcription factor and its promoter region and uses thereof
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20020187936A1 (en) 2001-05-17 2002-12-12 Board Of Trustees For The University Of Illinois Methods of treating liver disease and liver damage with growth hormone and foxM1B
WO2002099076A2 (en) * 2001-06-04 2002-12-12 Basf Plant Science Gmbh Sugar and lipid metabolism regulators in plants ii
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1462456A4 (en) * 2001-12-10 2005-09-21 Greenpeptide Co Ltd TUMOR ANTIGENS
AU2003272247A1 (en) 2002-08-28 2004-03-19 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CN1703524B (zh) 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 与人胰腺癌相关的基因和多肽
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
ATE402956T1 (de) * 2002-10-02 2008-08-15 Hoffmann La Roche Neue, mhc klasse ii assoziierte peptide
WO2004100977A1 (en) 2003-03-25 2004-11-25 The Board Of Trustees Of The University Of Illinois Inhibition of tumor cell proliferation by foxm1b inhibitors
EP1668354A2 (en) * 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Method of diagnosing breast cancer
JP4046067B2 (ja) * 2003-11-04 2008-02-13 ソニー株式会社 固体撮像素子の製造方法
JP5060134B2 (ja) * 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
CA2555145A1 (en) * 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
CN1977052B (zh) * 2004-03-23 2012-09-05 肿瘤疗法科学股份有限公司 与kif11基因相关的双-链分子及载体
JP2007530921A (ja) 2004-03-24 2007-11-01 オンコセラピー・サイエンス株式会社 非小細胞肺癌に対する腫瘍マーカーおよび治療標的としてのａｄａｍ８
US20090208517A1 (en) * 2004-08-19 2009-08-20 Bernhard Moser Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy
JP2006141208A (ja) * 2004-11-16 2006-06-08 Univ Of Tokushima 多発性骨髄腫、白血病、悪性リンパ腫、肺癌等の免疫療法剤
JP5109131B2 (ja) * 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
EP2298933A1 (en) 2005-07-27 2011-03-23 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
EP1806413A1 (en) 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
JP2009536516A (ja) * 2006-04-20 2009-10-15 オンコセラピー・サイエンス株式会社 肺癌の治療標的としてのＮＭＵ−ＧＨＳＲ１ｂ／ＮＴＳＲ１発癌シグナル伝達経路
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
WO2009025196A1 (ja) 2007-08-20 2009-02-26 Oncotherapy Science, Inc. Foxm1ペプチドおよびこれを含む薬剤
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗

Also Published As

Publication number Publication date
KR101543624B1 (ko) 2015-08-11
JP5909767B2 (ja) 2016-04-27
KR20100044885A (ko) 2010-04-30
US9415096B2 (en) 2016-08-16
CN108117584A (zh) 2018-06-05
JP5555952B2 (ja) 2014-07-23
EP3263585A3 (en) 2018-02-28
CA2696597C (en) 2017-05-16
CN101835792B (zh) 2015-04-15
CN101835792A (zh) 2010-09-15
AU2008290049A1 (en) 2009-02-26
EP2189471A1 (en) 2010-05-26
CA2696597A1 (en) 2009-02-26
CN104774261B (zh) 2018-03-06
AU2008290049B2 (en) 2013-08-29
JPWO2009025196A1 (ja) 2010-11-25
BRPI0815577A2 (pt) 2015-03-03
RU2010110567A (ru) 2011-09-27
EP4032899A1 (en) 2022-07-27
CN104774261A (zh) 2015-07-15
EP3263585B1 (en) 2022-01-19
WO2009025196A1 (ja) 2009-02-26
US9073968B2 (en) 2015-07-07
US20140023672A1 (en) 2014-01-23
JP2014193893A (ja) 2014-10-09
EP3263585A2 (en) 2018-01-03
US8569244B2 (en) 2013-10-29
US20110195081A1 (en) 2011-08-11
CN108117584B (zh) 2021-08-24
SG183717A1 (en) 2012-09-27
IL203899A (en) 2016-10-31
EP2189471B1 (en) 2017-10-04
TWI558411B (zh) 2016-11-21
EP2189471A4 (en) 2010-09-01
US20150265689A1 (en) 2015-09-24
RU2487886C2 (ru) 2013-07-20
HK1244819A1 (zh) 2018-08-17
TW200922616A (en) 2009-06-01

Similar Documents

Publication Publication Date Title
MX2010002002A (es) Peptido foxm1 y agente medicinal que lo contiene.
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
NZ708990A (en) Method for activating helper t cell
GEP20176629B (en) Glucagon/glp-1 receptor co-agonists
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
EA201592264A1 (ru) Композиции, которые индуцируют хелперное действие т-клеток
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
TW200744642A (en) Novel peptides for use in the treatment of obesity
NZ599161A (en) Method for activation of helper t cell and composition for use in the method
WO2012054500A3 (en) Compositions for drug administration
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
BR112012013139A2 (pt) oligopeptídeos imp-3 e vacinas incluindo os mesmos
NZ594198A (en) Neil3 peptides and vaccines including the same
MX2020009150A (es) Anfifilos de cpg y usos de los mismos.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
MX2013014489A (es) Peptidos sema5b y vacunas que incluyen los mismos.
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration